nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—nephrolithiasis	0.853	1	CtDrD
Sorafenib—STK10—renal vein—nephrolithiasis	0.0144	0.179	CbGeAlD
Sorafenib—STK10—renal artery—nephrolithiasis	0.00966	0.12	CbGeAlD
Sorafenib—RET—parathyroid gland—nephrolithiasis	0.00416	0.0518	CbGeAlD
Sorafenib—UGT1A1—urine—nephrolithiasis	0.00256	0.0319	CbGeAlD
Sorafenib—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.00167	0.046	CcSEcCtD
Sorafenib—CYP2C19—urine—nephrolithiasis	0.00139	0.0173	CbGeAlD
Sorafenib—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00138	0.0382	CcSEcCtD
Sorafenib—CDK7—renal system—nephrolithiasis	0.00138	0.0172	CbGeAlD
Sorafenib—HIPK3—nephron tubule—nephrolithiasis	0.00128	0.016	CbGeAlD
Sorafenib—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.0012	0.0331	CcSEcCtD
Sorafenib—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00117	0.0324	CcSEcCtD
Sorafenib—HIPK3—renal system—nephrolithiasis	0.00117	0.0145	CbGeAlD
Sorafenib—CYP1A2—urine—nephrolithiasis	0.00113	0.0141	CbGeAlD
Sorafenib—HIPK3—kidney—nephrolithiasis	0.00113	0.014	CbGeAlD
Sorafenib—EPHX2—nephron tubule—nephrolithiasis	0.0011	0.0137	CbGeAlD
Sorafenib—CYP2C9—urine—nephrolithiasis	0.00107	0.0134	CbGeAlD
Sorafenib—EPHX2—cortex of kidney—nephrolithiasis	0.00094	0.0117	CbGeAlD
Sorafenib—UGT1A9—renal system—nephrolithiasis	0.000913	0.0114	CbGeAlD
Sorafenib—MKNK2—nephron tubule—nephrolithiasis	0.000897	0.0112	CbGeAlD
Sorafenib—UGT1A9—kidney—nephrolithiasis	0.000883	0.011	CbGeAlD
Sorafenib—FLT4—cortex of kidney—nephrolithiasis	0.000848	0.0106	CbGeAlD
Sorafenib—FGFR1—cortex of kidney—nephrolithiasis	0.000836	0.0104	CbGeAlD
Sorafenib—CYP3A4—urine—nephrolithiasis	0.00082	0.0102	CbGeAlD
Sorafenib—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.000815	0.0225	CcSEcCtD
Sorafenib—MKNK2—renal system—nephrolithiasis	0.000815	0.0102	CbGeAlD
Sorafenib—RALBP1—nephron tubule—nephrolithiasis	0.00081	0.0101	CbGeAlD
Sorafenib—CYP2D6—urine—nephrolithiasis	0.000807	0.0101	CbGeAlD
Sorafenib—RET—renal system—nephrolithiasis	0.000795	0.00991	CbGeAlD
Sorafenib—MAP3K7—cortex of kidney—nephrolithiasis	0.000792	0.00987	CbGeAlD
Sorafenib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000772	0.0213	CcSEcCtD
Sorafenib—FLT1—nephron tubule—nephrolithiasis	0.00077	0.0096	CbGeAlD
Sorafenib—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.000769	0.0212	CcSEcCtD
Sorafenib—RET—kidney—nephrolithiasis	0.000768	0.00958	CbGeAlD
Sorafenib—MKNK2—cortex of kidney—nephrolithiasis	0.000767	0.00956	CbGeAlD
Sorafenib—RAF1—nephron tubule—nephrolithiasis	0.000766	0.00954	CbGeAlD
Sorafenib—MKNK1—cortex of kidney—nephrolithiasis	0.000758	0.00944	CbGeAlD
Sorafenib—RALBP1—renal system—nephrolithiasis	0.000736	0.00917	CbGeAlD
Sorafenib—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.000729	0.0201	CcSEcCtD
Sorafenib—RALBP1—kidney—nephrolithiasis	0.000711	0.00887	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.00071	0.00885	CbGeAlD
Sorafenib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000705	0.0195	CcSEcCtD
Sorafenib—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.000702	0.0194	CcSEcCtD
Sorafenib—FLT1—renal system—nephrolithiasis	0.0007	0.00872	CbGeAlD
Sorafenib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.0007	0.0193	CcSEcCtD
Sorafenib—RAF1—renal system—nephrolithiasis	0.000696	0.00867	CbGeAlD
Sorafenib—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000695	0.0192	CcSEcCtD
Sorafenib—RALBP1—cortex of kidney—nephrolithiasis	0.000693	0.00864	CbGeAlD
Sorafenib—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000693	0.0191	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.000693	0.0191	CcSEcCtD
Sorafenib—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.000681	0.0188	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000678	0.0187	CcSEcCtD
Sorafenib—FLT1—kidney—nephrolithiasis	0.000677	0.00843	CbGeAlD
Sorafenib—RAF1—kidney—nephrolithiasis	0.000673	0.00839	CbGeAlD
Sorafenib—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.000665	0.0183	CcSEcCtD
Sorafenib—STK10—renal system—nephrolithiasis	0.000663	0.00826	CbGeAlD
Sorafenib—FLT1—cortex of kidney—nephrolithiasis	0.000659	0.00821	CbGeAlD
Sorafenib—PDGFRA—renal system—nephrolithiasis	0.000656	0.00818	CbGeAlD
Sorafenib—RAF1—cortex of kidney—nephrolithiasis	0.000655	0.00817	CbGeAlD
Sorafenib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000652	0.018	CcSEcCtD
Sorafenib—EPHB6—cortex of kidney—nephrolithiasis	0.000651	0.00812	CbGeAlD
Sorafenib—KDR—nephron tubule—nephrolithiasis	0.000651	0.00811	CbGeAlD
Sorafenib—STK10—kidney—nephrolithiasis	0.000641	0.00798	CbGeAlD
Sorafenib—UGT1A1—renal system—nephrolithiasis	0.000626	0.0078	CbGeAlD
Sorafenib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.000622	0.0172	CcSEcCtD
Sorafenib—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000612	0.0169	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.000608	0.00758	CbGeAlD
Sorafenib—UGT1A1—kidney—nephrolithiasis	0.000605	0.00754	CbGeAlD
Sorafenib—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000596	0.0165	CcSEcCtD
Sorafenib—KDR—renal system—nephrolithiasis	0.000592	0.00738	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.000588	0.0162	CcSEcCtD
Sorafenib—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.000584	0.0161	CcSEcCtD
Sorafenib—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.000583	0.0161	CcSEcCtD
Sorafenib—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.000581	0.016	CcSEcCtD
Sorafenib—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000581	0.016	CcSEcCtD
Sorafenib—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.000578	0.0159	CcSEcCtD
Sorafenib—KIT—nephron tubule—nephrolithiasis	0.000577	0.00719	CbGeAlD
Sorafenib—KDR—kidney—nephrolithiasis	0.000572	0.00713	CbGeAlD
Sorafenib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000559	0.0154	CcSEcCtD
Sorafenib—MAP2K5—cortex of kidney—nephrolithiasis	0.000557	0.00694	CbGeAlD
Sorafenib—KDR—cortex of kidney—nephrolithiasis	0.000557	0.00694	CbGeAlD
Sorafenib—KIT—renal system—nephrolithiasis	0.000524	0.00654	CbGeAlD
Sorafenib—PDGFRB—renal system—nephrolithiasis	0.000512	0.00638	CbGeAlD
Sorafenib—KIT—kidney—nephrolithiasis	0.000507	0.00632	CbGeAlD
Sorafenib—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.000503	0.0139	CcSEcCtD
Sorafenib—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000496	0.0137	CcSEcCtD
Sorafenib—PDGFRB—kidney—nephrolithiasis	0.000495	0.00617	CbGeAlD
Sorafenib—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000494	0.0136	CcSEcCtD
Sorafenib—KIT—cortex of kidney—nephrolithiasis	0.000494	0.00615	CbGeAlD
Sorafenib—PDGFRB—cortex of kidney—nephrolithiasis	0.000482	0.00601	CbGeAlD
Sorafenib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.000475	0.0131	CcSEcCtD
Sorafenib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00047	0.013	CcSEcCtD
Sorafenib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000463	0.0128	CcSEcCtD
Sorafenib—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000454	0.0125	CcSEcCtD
Sorafenib—ABCC4—nephron tubule—nephrolithiasis	0.000449	0.00559	CbGeAlD
Sorafenib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000445	0.0123	CcSEcCtD
Sorafenib—ABCC2—nephron tubule—nephrolithiasis	0.000434	0.00541	CbGeAlD
Sorafenib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000428	0.0118	CcSEcCtD
Sorafenib—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000423	0.0117	CcSEcCtD
Sorafenib—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000415	0.0115	CcSEcCtD
Sorafenib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000415	0.0114	CcSEcCtD
Sorafenib—ABCC4—renal system—nephrolithiasis	0.000408	0.00508	CbGeAlD
Sorafenib—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000407	0.0112	CcSEcCtD
Sorafenib—Cough—Hydrochlorothiazide—nephrolithiasis	0.000404	0.0112	CcSEcCtD
Sorafenib—ABCC2—renal system—nephrolithiasis	0.000395	0.00492	CbGeAlD
Sorafenib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000394	0.0109	CcSEcCtD
Sorafenib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000394	0.0109	CcSEcCtD
Sorafenib—ABCC4—kidney—nephrolithiasis	0.000394	0.00491	CbGeAlD
Sorafenib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000386	0.0106	CcSEcCtD
Sorafenib—ABCC4—cortex of kidney—nephrolithiasis	0.000384	0.00479	CbGeAlD
Sorafenib—HTR2B—cortex of kidney—nephrolithiasis	0.000382	0.00476	CbGeAlD
Sorafenib—ABCC2—kidney—nephrolithiasis	0.000382	0.00476	CbGeAlD
Sorafenib—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000378	0.0104	CcSEcCtD
Sorafenib—Shock—Hydrochlorothiazide—nephrolithiasis	0.000372	0.0103	CcSEcCtD
Sorafenib—ABCC2—cortex of kidney—nephrolithiasis	0.000372	0.00463	CbGeAlD
Sorafenib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00037	0.0102	CcSEcCtD
Sorafenib—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00036	0.00995	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000344	0.00951	CcSEcCtD
Sorafenib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000337	0.0093	CcSEcCtD
Sorafenib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000333	0.00919	CcSEcCtD
Sorafenib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000329	0.00907	CcSEcCtD
Sorafenib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000326	0.009	CcSEcCtD
Sorafenib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000323	0.00892	CcSEcCtD
Sorafenib—Pain—Hydrochlorothiazide—nephrolithiasis	0.000323	0.00892	CcSEcCtD
Sorafenib—ABCG2—nephron tubule—nephrolithiasis	0.000317	0.00395	CbGeAlD
Sorafenib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000309	0.00853	CcSEcCtD
Sorafenib—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.0003	0.00829	CcSEcCtD
Sorafenib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000299	0.00825	CcSEcCtD
Sorafenib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000299	0.00825	CcSEcCtD
Sorafenib—CYP2C8—renal system—nephrolithiasis	0.000296	0.00369	CbGeAlD
Sorafenib—CYP3A5—nephron tubule—nephrolithiasis	0.000294	0.00366	CbGeAlD
Sorafenib—CYP2B6—nephron tubule—nephrolithiasis	0.000292	0.00364	CbGeAlD
Sorafenib—CYP2C8—kidney—nephrolithiasis	0.000286	0.00357	CbGeAlD
Sorafenib—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000278	0.00769	CcSEcCtD
Sorafenib—CYP1A2—renal system—nephrolithiasis	0.000277	0.00345	CbGeAlD
Sorafenib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000271	0.00749	CcSEcCtD
Sorafenib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000267	0.00738	CcSEcCtD
Sorafenib—CYP3A5—renal system—nephrolithiasis	0.000267	0.00333	CbGeAlD
Sorafenib—CYP2B6—renal system—nephrolithiasis	0.000266	0.00331	CbGeAlD
Sorafenib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000259	0.00714	CcSEcCtD
Sorafenib—CYP3A5—kidney—nephrolithiasis	0.000258	0.00322	CbGeAlD
Sorafenib—CYP2B6—kidney—nephrolithiasis	0.000257	0.0032	CbGeAlD
Sorafenib—CYP3A5—cortex of kidney—nephrolithiasis	0.000252	0.00314	CbGeAlD
Sorafenib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00025	0.0069	CcSEcCtD
Sorafenib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00024	0.00663	CcSEcCtD
Sorafenib—Rash—Hydrochlorothiazide—nephrolithiasis	0.000238	0.00658	CcSEcCtD
Sorafenib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000238	0.00657	CcSEcCtD
Sorafenib—Headache—Hydrochlorothiazide—nephrolithiasis	0.000237	0.00654	CcSEcCtD
Sorafenib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000225	0.0062	CcSEcCtD
Sorafenib—CYP3A4—renal system—nephrolithiasis	0.000201	0.0025	CbGeAlD
Sorafenib—CYP2D6—renal system—nephrolithiasis	0.000197	0.00246	CbGeAlD
Sorafenib—CYP3A4—kidney—nephrolithiasis	0.000194	0.00242	CbGeAlD
Sorafenib—CYP2D6—kidney—nephrolithiasis	0.000191	0.00238	CbGeAlD
Sorafenib—ABCB1—nephron tubule—nephrolithiasis	0.000156	0.00195	CbGeAlD
Sorafenib—ABCB1—renal system—nephrolithiasis	0.000142	0.00177	CbGeAlD
Sorafenib—ABCB1—kidney—nephrolithiasis	0.000137	0.00171	CbGeAlD
Sorafenib—ABCB1—cortex of kidney—nephrolithiasis	0.000134	0.00167	CbGeAlD
Sorafenib—RAF1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	6.76e-05	0.00221	CbGpPWpGaD
Sorafenib—CDK7—Disease—ATP6V0A4—nephrolithiasis	6.72e-05	0.00219	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.68e-05	0.00218	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DGKH—nephrolithiasis	6.68e-05	0.00218	CbGpPWpGaD
Sorafenib—KDR—Extracellular matrix organization—SPP1—nephrolithiasis	6.59e-05	0.00215	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by PDGF—SPP1—nephrolithiasis	6.53e-05	0.00213	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by PDGF—SPP1—nephrolithiasis	6.52e-05	0.00213	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	6.37e-05	0.00208	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	6.34e-05	0.00207	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	6.34e-05	0.00207	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—RGS14—nephrolithiasis	6.32e-05	0.00207	CbGpPWpGaD
Sorafenib—RAF1—BDNF signaling pathway—SPP1—nephrolithiasis	6.31e-05	0.00206	CbGpPWpGaD
Sorafenib—PDGFRA—Focal Adhesion—SPP1—nephrolithiasis	6.3e-05	0.00206	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—RGS14—nephrolithiasis	6.08e-05	0.00199	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	6.04e-05	0.00197	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	6.04e-05	0.00197	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	6.02e-05	0.00197	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	6.02e-05	0.00197	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—CHRM3—nephrolithiasis	6.02e-05	0.00197	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DGKH—nephrolithiasis	6.01e-05	0.00196	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.01e-05	0.00196	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ADCY10—nephrolithiasis	5.99e-05	0.00196	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ADCY10—nephrolithiasis	5.93e-05	0.00194	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—CHRM3—nephrolithiasis	5.92e-05	0.00193	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—RGS14—nephrolithiasis	5.92e-05	0.00193	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—RGS14—nephrolithiasis	5.91e-05	0.00193	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	5.89e-05	0.00192	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	5.89e-05	0.00192	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by PDGF—SPP1—nephrolithiasis	5.87e-05	0.00192	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—CHRM3—nephrolithiasis	5.83e-05	0.0019	CbGpPWpGaD
Sorafenib—ABCC4—Transmembrane transport of small molecules—AQP1—nephrolithiasis	5.72e-05	0.00187	CbGpPWpGaD
Sorafenib—PDGFRB—Focal Adhesion—SPP1—nephrolithiasis	5.67e-05	0.00185	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	5.62e-05	0.00183	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	5.55e-05	0.00181	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	5.55e-05	0.00181	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—PTH—nephrolithiasis	5.5e-05	0.0018	CbGpPWpGaD
Sorafenib—BRAF—Disease—SLC26A1—nephrolithiasis	5.46e-05	0.00178	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—PTH—nephrolithiasis	5.42e-05	0.00177	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ADCY10—nephrolithiasis	5.4e-05	0.00176	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ADCY10—nephrolithiasis	5.4e-05	0.00176	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	5.38e-05	0.00176	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—PTH—nephrolithiasis	5.33e-05	0.00174	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	5.25e-05	0.00172	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	5.25e-05	0.00172	CbGpPWpGaD
Sorafenib—RAF1—Signaling by PDGF—SPP1—nephrolithiasis	5.23e-05	0.00171	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ADCY10—nephrolithiasis	5.13e-05	0.00167	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ADCY10—nephrolithiasis	5.11e-05	0.00167	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	5.1e-05	0.00167	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—RGS14—nephrolithiasis	5.09e-05	0.00166	CbGpPWpGaD
Sorafenib—RAF1—Focal Adhesion—SPP1—nephrolithiasis	5.05e-05	0.00165	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—RGS14—nephrolithiasis	5.05e-05	0.00165	CbGpPWpGaD
Sorafenib—KIT—Disease—SLC26A1—nephrolithiasis	4.97e-05	0.00162	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	4.94e-05	0.00161	CbGpPWpGaD
Sorafenib—BRAF—Disease—ATP6V0A4—nephrolithiasis	4.87e-05	0.00159	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	4.85e-05	0.00159	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—CHRM3—nephrolithiasis	4.83e-05	0.00158	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	4.83e-05	0.00158	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	4.81e-05	0.00157	CbGpPWpGaD
Sorafenib—FGFR1—Disease—SLC26A1—nephrolithiasis	4.72e-05	0.00154	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—SLC26A1—nephrolithiasis	4.7e-05	0.00154	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DGKH—nephrolithiasis	4.7e-05	0.00154	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ADCY10—nephrolithiasis	4.61e-05	0.0015	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RGS14—nephrolithiasis	4.59e-05	0.0015	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RGS14—nephrolithiasis	4.59e-05	0.0015	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	4.52e-05	0.00148	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	4.52e-05	0.00148	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	4.44e-05	0.00145	CbGpPWpGaD
Sorafenib—KIT—Disease—ATP6V0A4—nephrolithiasis	4.43e-05	0.00145	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—PTH—nephrolithiasis	4.42e-05	0.00144	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ADCY10—nephrolithiasis	4.39e-05	0.00143	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RGS14—nephrolithiasis	4.36e-05	0.00142	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RGS14—nephrolithiasis	4.35e-05	0.00142	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CHRM3—nephrolithiasis	4.35e-05	0.00142	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—GRHPR—nephrolithiasis	4.29e-05	0.0014	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—GRHPR—nephrolithiasis	4.29e-05	0.0014	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DGKH—nephrolithiasis	4.27e-05	0.0014	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—SLC26A1—nephrolithiasis	4.24e-05	0.00138	CbGpPWpGaD
Sorafenib—FGFR1—Disease—ATP6V0A4—nephrolithiasis	4.2e-05	0.00137	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	4.2e-05	0.00137	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—ATP6V0A4—nephrolithiasis	4.19e-05	0.00137	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.11e-05	0.00134	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DGKH—nephrolithiasis	4.11e-05	0.00134	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ADCY10—nephrolithiasis	4.11e-05	0.00134	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—ATP6V0A4—nephrolithiasis	4e-05	0.00131	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DGKH—nephrolithiasis	4e-05	0.00131	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DGKH—nephrolithiasis	3.99e-05	0.0013	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—PTH—nephrolithiasis	3.98e-05	0.0013	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RGS14—nephrolithiasis	3.92e-05	0.00128	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AGXT—nephrolithiasis	3.83e-05	0.00125	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AGXT—nephrolithiasis	3.83e-05	0.00125	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	3.79e-05	0.00124	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ATP6V0A4—nephrolithiasis	3.78e-05	0.00123	CbGpPWpGaD
Sorafenib—RAF1—Disease—SLC26A1—nephrolithiasis	3.78e-05	0.00123	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RGS14—nephrolithiasis	3.74e-05	0.00122	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—GRHPR—nephrolithiasis	3.64e-05	0.00119	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—GRHPR—nephrolithiasis	3.61e-05	0.00118	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	3.54e-05	0.00116	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RGS14—nephrolithiasis	3.49e-05	0.00114	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	3.45e-05	0.00113	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.44e-05	0.00112	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DGKH—nephrolithiasis	3.44e-05	0.00112	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	3.43e-05	0.00112	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	3.43e-05	0.00112	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.41e-05	0.00111	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DGKH—nephrolithiasis	3.41e-05	0.00111	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CHRM3—nephrolithiasis	3.4e-05	0.00111	CbGpPWpGaD
Sorafenib—RAF1—Disease—ATP6V0A4—nephrolithiasis	3.37e-05	0.0011	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—SLC26A1—nephrolithiasis	3.25e-05	0.00106	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—APRT—nephrolithiasis	3.25e-05	0.00106	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—APRT—nephrolithiasis	3.25e-05	0.00106	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—SLC26A1—nephrolithiasis	3.25e-05	0.00106	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AGXT—nephrolithiasis	3.25e-05	0.00106	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AGXT—nephrolithiasis	3.22e-05	0.00105	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	3.19e-05	0.00104	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	3.19e-05	0.00104	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—PTH—nephrolithiasis	3.11e-05	0.00102	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DGKH—nephrolithiasis	3.1e-05	0.00101	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.1e-05	0.00101	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DGKH—nephrolithiasis	3.1e-05	0.00101	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.1e-05	0.00101	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CHRM3—nephrolithiasis	3.09e-05	0.00101	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	3.01e-05	0.000984	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CHRM3—nephrolithiasis	2.97e-05	0.00097	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DGKH—nephrolithiasis	2.94e-05	0.000962	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.94e-05	0.000962	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.94e-05	0.000959	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DGKH—nephrolithiasis	2.94e-05	0.000959	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CHRM3—nephrolithiasis	2.89e-05	0.000945	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CHRM3—nephrolithiasis	2.89e-05	0.000943	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	2.84e-05	0.000927	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	2.84e-05	0.000927	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PTH—nephrolithiasis	2.82e-05	0.000922	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—APRT—nephrolithiasis	2.76e-05	0.000901	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	2.76e-05	0.000901	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	2.74e-05	0.000896	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—SLC26A1—nephrolithiasis	2.74e-05	0.000893	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—APRT—nephrolithiasis	2.74e-05	0.000893	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—SPP1—nephrolithiasis	2.72e-05	0.000888	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTH—nephrolithiasis	2.71e-05	0.000887	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—SPP1—nephrolithiasis	2.68e-05	0.000874	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GRHPR—nephrolithiasis	2.67e-05	0.000872	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.65e-05	0.000864	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DGKH—nephrolithiasis	2.65e-05	0.000864	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTH—nephrolithiasis	2.65e-05	0.000864	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PTH—nephrolithiasis	2.64e-05	0.000862	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GRHPR—nephrolithiasis	2.61e-05	0.000852	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.52e-05	0.000824	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DGKH—nephrolithiasis	2.52e-05	0.000824	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	2.51e-05	0.00082	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	2.49e-05	0.000814	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CHRM3—nephrolithiasis	2.49e-05	0.000812	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CHRM3—nephrolithiasis	2.46e-05	0.000805	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AGXT—nephrolithiasis	2.38e-05	0.000777	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DGKH—nephrolithiasis	2.36e-05	0.00077	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.36e-05	0.00077	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AGXT—nephrolithiasis	2.33e-05	0.00076	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AQP1—nephrolithiasis	2.32e-05	0.000757	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AQP1—nephrolithiasis	2.32e-05	0.000757	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	2.28e-05	0.000744	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTH—nephrolithiasis	2.27e-05	0.000743	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	2.27e-05	0.000741	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	2.26e-05	0.000738	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTH—nephrolithiasis	2.25e-05	0.000736	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CHRM3—nephrolithiasis	2.24e-05	0.000733	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CHRM3—nephrolithiasis	2.24e-05	0.000733	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—SPP1—nephrolithiasis	2.22e-05	0.000724	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CHRM3—nephrolithiasis	2.13e-05	0.000695	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CHRM3—nephrolithiasis	2.12e-05	0.000693	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CHRM3—nephrolithiasis	2.1e-05	0.000685	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CHRM3—nephrolithiasis	2.1e-05	0.000685	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTH—nephrolithiasis	2.05e-05	0.00067	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTH—nephrolithiasis	2.05e-05	0.00067	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	2.04e-05	0.000665	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	2.04e-05	0.000665	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APRT—nephrolithiasis	2.02e-05	0.000661	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	2.02e-05	0.000661	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GRHPR—nephrolithiasis	2.02e-05	0.000659	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGXT—nephrolithiasis	2.01e-05	0.000658	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—SPP1—nephrolithiasis	2e-05	0.000652	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	1.98e-05	0.000646	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APRT—nephrolithiasis	1.98e-05	0.000646	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GRHPR—nephrolithiasis	1.97e-05	0.000643	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AQP1—nephrolithiasis	1.97e-05	0.000642	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AQP1—nephrolithiasis	1.95e-05	0.000637	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTH—nephrolithiasis	1.95e-05	0.000636	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTH—nephrolithiasis	1.94e-05	0.000634	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CHRM3—nephrolithiasis	1.91e-05	0.000625	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GRHPR—nephrolithiasis	1.86e-05	0.000606	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GRHPR—nephrolithiasis	1.84e-05	0.000601	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CHRM3—nephrolithiasis	1.82e-05	0.000596	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGXT—nephrolithiasis	1.8e-05	0.000587	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CHRM3—nephrolithiasis	1.78e-05	0.000581	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CHRM3—nephrolithiasis	1.76e-05	0.000576	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGXT—nephrolithiasis	1.75e-05	0.000573	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTH—nephrolithiasis	1.75e-05	0.000571	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	1.71e-05	0.000559	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APRT—nephrolithiasis	1.71e-05	0.000559	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CHRM3—nephrolithiasis	1.7e-05	0.000557	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTH—nephrolithiasis	1.67e-05	0.000545	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGXT—nephrolithiasis	1.65e-05	0.00054	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGXT—nephrolithiasis	1.64e-05	0.000535	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GRHPR—nephrolithiasis	1.57e-05	0.000513	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTH—nephrolithiasis	1.56e-05	0.000509	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	1.53e-05	0.000499	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APRT—nephrolithiasis	1.53e-05	0.000499	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APRT—nephrolithiasis	1.49e-05	0.000487	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC26A1—nephrolithiasis	1.49e-05	0.000487	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	1.47e-05	0.000481	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AQP1—nephrolithiasis	1.44e-05	0.000471	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AQP1—nephrolithiasis	1.41e-05	0.00046	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APRT—nephrolithiasis	1.41e-05	0.000459	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	1.41e-05	0.000459	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGXT—nephrolithiasis	1.4e-05	0.000458	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	1.39e-05	0.000455	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APRT—nephrolithiasis	1.39e-05	0.000455	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SPP1—nephrolithiasis	1.36e-05	0.000445	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTH—nephrolithiasis	1.35e-05	0.00044	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SPP1—nephrolithiasis	1.33e-05	0.000434	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CHRM3—nephrolithiasis	1.3e-05	0.000426	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CHRM3—nephrolithiasis	1.27e-05	0.000416	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AQP1—nephrolithiasis	1.22e-05	0.000399	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.21e-05	0.000396	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	1.19e-05	0.000389	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APRT—nephrolithiasis	1.19e-05	0.000389	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SPP1—nephrolithiasis	1.14e-05	0.000373	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SPP1—nephrolithiasis	1.13e-05	0.00037	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	1.1e-05	0.00036	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AQP1—nephrolithiasis	1.09e-05	0.000356	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.08e-05	0.000353	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AQP1—nephrolithiasis	1.06e-05	0.000347	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SPP1—nephrolithiasis	1.03e-05	0.000336	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SPP1—nephrolithiasis	1.03e-05	0.000336	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AQP1—nephrolithiasis	1e-05	0.000327	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AQP1—nephrolithiasis	9.93e-06	0.000324	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CHRM3—nephrolithiasis	9.85e-06	0.000322	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SPP1—nephrolithiasis	9.77e-06	0.000319	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SPP1—nephrolithiasis	9.75e-06	0.000318	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CHRM3—nephrolithiasis	9.61e-06	0.000314	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APRT—nephrolithiasis	9.19e-06	0.0003	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	9.19e-06	0.0003	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CHRM3—nephrolithiasis	9.06e-06	0.000296	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CHRM3—nephrolithiasis	8.98e-06	0.000293	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SPP1—nephrolithiasis	8.78e-06	0.000287	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AQP1—nephrolithiasis	8.49e-06	0.000277	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SPP1—nephrolithiasis	8.38e-06	0.000274	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SPP1—nephrolithiasis	7.83e-06	0.000256	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CHRM3—nephrolithiasis	7.68e-06	0.000251	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	6.76e-06	0.000221	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AQP1—nephrolithiasis	6.55e-06	0.000214	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	5.92e-06	0.000193	CbGpPWpGaD
